Nitric oxide donors for the treatment of osteoporosis

Current Osteoporosis Reports

Volumn 10, Issue 1, 2012, Pages 86-92

  Jamal, Sophie A ^a   Hamilton, Celeste J ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Fracture; Nitric oxide; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CONJUGATED ESTROGEN; DENOSUMAB; ESTRADIOL; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; NITRATE; NITRIC OXIDE; NITRO BID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; NITRIC OXIDE DONOR;

BONE DENSITY; BONE DISEASE; BONE REMODELING; BONE TURNOVER; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FRACTURE; FRAGILITY FRACTURE; HEADACHE; HIP FRACTURE; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; ANIMAL; BONE; DRUG EFFECT; METHODOLOGY; RADIOGRAPHY; RISK ASSESSMENT;

ANIMALS; BONE AND BONES; BONE REMODELING; DIPHOSPHONATES; HUMANS; NITRIC OXIDE DONORS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862252217     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-011-0087-7     Document Type: Review

References (57)

1. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fracture. Epidemiol Rev. 1985;7:178-208.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-33. (Pubitemid 44607392)
3. Melton LJI, Cooper C. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. 2nd ed. San Diego: Academic; 2001. p. 557-67.
4. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407-13. (Pubitemid 27443065)
5. Cummings SR. A 55-year-old woman with osteopenia. Jama. 2006;296(21):2601-10. (Pubitemid 44903863)
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41. (Pubitemid 26411651)
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama. 1998;280(24):2077-82. (Pubitemid 29014065)
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama. 1999;282(14):1344-52. (Pubitemid 29483192)
9. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22. (Pubitemid 46698462)
10. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361 (8):756-65.
11. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama. 1999;282 (7):637-45. (Pubitemid 29384151)
12. Neer RM, Arnaud CD, Zanchetta JR. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. (Pubitemid 32402100)
13. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000;8:1318-21. (Pubitemid 30129799)
14. Cryer R, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77(10):1031-43.
15. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000;160(4):517-25. (Pubitemid 30112275)
16. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503-8. (Pubitemid 47457426)
17. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 25(11):2267-94.
18. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. 2002;288(3):321-33.
19. Cummings SR, Cosman F, Jamal SA, eds. Osteoporosis. An evidenced-based guide to prevention and management. Philadelphia: American College of Physicians 2002.
20. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama. 1999;281(23):2189-97. (Pubitemid 29275701)
21. Evans DM, Ralston SH. Nitric oxide and bone. J Bone Miner Res. 1996;11(3):300-5. (Pubitemid 26076379)
22. Chae HJ, Park RK, Chung HT, Kang JS, Kim MS, Choi DY, et al. Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol. 1997;49(9):897-902.
23. Evans CH, Stefanovic-Racic M, Lancaster J. Nitric oxide and its role in orthopaedic disease. Clin Orthop. 1995;312:275-94.
24. Feelisch M. Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Hear J. 1993;14:123-32. (Pubitemid 23362605)
25. Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, et al. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proceedings of the National Academy of Sciences USA. 1995;92:2954-8.
26. Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation and communication: a role for nitric oxide. J Cell Biochem. 1995;57:399-408.
27. Kasten TP, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko TP, et al. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A. 1994;91(9):3569-73. (Pubitemid 24139471)
28. Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE. Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest. 1994;93(4):1465-72. (Pubitemid 24116382)
29. MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A. 1991;88 (7):2936-40. (Pubitemid 21916535)
30. Ralston SH. Osteoporosis. BMJ. 1997;315(7106):469-72.
31. Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995;10(7):1040-9.
32. Collin-Osdoby P, Li L, Rothe L, Anderson F, Kirsch D, Oursler MJ, et al. Inhibition of avian osteoclast bone resorption by monoclonal antibody 121 F: a mechanism involving the osteoclast free radical system. J Bone Miner Res. 1998;13(1):67-78. (Pubitemid 28063115)
33. Ralston SH. The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Br J Rheumatol. 1997;36(8):831-8.
34. Chow JW, Fox SW, Lean JM, Chambers TJ. Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res. 1998;13(6):1039-44. (Pubitemid 28265283)
35. Ake Y, Saegusa Y, Matsubara T, Mizuno K. Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci. 1994;40(3-4):125-37.
36. Aguirre J, Buttery L, O'Shaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M, et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol. 2001;158 (1):247-57. (Pubitemid 32096490)
37. Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology. 2001;142(2):760-6. (Pubitemid 32222425)
38. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996;18(4):301-4. (Pubitemid 26149339)
39. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998;13(11):1755-9. (Pubitemid 28492006)
40. Abshagen A, Sporl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol. 1981;19:423-9.
41. Wimalawansa SJ, Chapa T, Wimalawansa S, Fang L, Yallampalli C. Dose and frequency effects of nitric oxide donor nitroglycerine on bone. Seventy- ninth Annual Meeting of the Endocrine Society, Minneapolis, USA. 1997:(abst P3-248).
42. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767-73.
43. Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG, et al. Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab. 95(4):1924-31.
44. Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res. 2006;21(11):1811-7. (Pubitemid 46141238)
45. Jamal SA, Cummings SR, Hawker GA. The effects of isosorbide mononitrate on bone turnover: A randomized controlled trial. J Bone Miner Res. 2004;19(9):1512-7. This is a randomized trial that reported on the effects of the NO donor ISMO on bone turnover markers in healthy women. (Pubitemid 41094353)
46. Fung H. Pharmacokinetics of nitroglycerin and long-acting nitrate esters. Am J Med. 1983;12:13-20. (Pubitemid 13064815)
47. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovascular Drugs and Therapy. 1997;10:734-42.
48. Clowes JA, Eastell R. Markers of bone turnover and laboratory evaluation of secondary osteoporosis. In: Cummings SR, Cosman F, Jamal SA, editors. Osteoporosis: an evidenced-based guide to prevention and management. Philadelphia: American College of Physicians; 2002. p. 59-82.
49. Looker AC, Bauer DC, Chesnut 3rd CH, Gundberg CM, Hochberg MC, Klee G, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11(6):467-80.
50. Wimalawansa SJ. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res. 2000;15(11):2240-4.
51. Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. Jama. 305(8):800-7. This is a randomized trial that reported on the effects on the NO donor nitroglycerin on BMD, bone geometry, and bone turnover markers.
52. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in post-menopausal women with low bone density: Relations between density, cortical and trabecular micro-architecture, biomechanics, and bone turnover. J Bone Miner Res. 2010;25(12):2267-528.
53. Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int. May 11.
54. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 25(8):1886-94.
55. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349 (4):327-34. (Pubitemid 36886238)
56. Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, et al. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res. 2008;23(8):1326-33. (Pubitemid 352040188)
57. Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009;94(9):3356-64.